The mRNA Writing On The Wall, GSK Expands CureVac Alliance Into Next-Gen COVID-19 Vaccines
Includes 100m Dose Boost To CureVac's COVID-19 Manufacturing
Executive Summary
After major setbacks to its existing COVID-19 vaccine platform, GSK is expanding its presence in mRNA, which increasingly looks to be the future.
You may also be interested in...
Novartis Teams Up With CureVac To Make COVID-19 Vaccine
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.
After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.
EMA Starts Rolling Review Of CureVac’s COVID-19 Vaccine
CureVac has submitted the pre-clinical data package for its COVID-19 vaccine to the European Medicines Agency, which will be reviewing the data on a rolling basis.